title: Recombinant bacterial lipoproteins as vaccine candidates.
abstract: Recombinant bacterial lipoproteins (RLP) with built-in immuno-stimulating properties for novel subunit vaccine development are reviewed. This platform technology offers the following advantages: easily converts antigens into highly immunogenic RLP using a fusion sequence containing lipobox; the lipid moiety of RLP is recognized as the danger signals in the immune system through the Toll-like receptor 2, so both innate and adaptive immune responses can be induced by RLP; serves as an efficient and cost-effective bioprocess for producing RLP in Escherichia coli and the feasibility and safety of this core platform technology has been successfully demonstrated in animal model studies including meningococcal group B subunit vaccine, dengue subunit vaccine, novel subunit vaccine against Clostridium difficile-associated diseases and HPV-based immunotherapeutic vaccines.
authors.affiliation: a Vaccine R&D Center, National Health Research Institutes, Zhunan Town, Miaoli 350, Taiwan.
authors.forename: Chih-Hsiang
authors.initials: CH
authors.lastname: Leng
authors.affiliation: a Vaccine R&D Center, National Health Research Institutes, Zhunan Town, Miaoli 350, Taiwan.
authors.forename: Shih-Jen
authors.initials: SJ
authors.lastname: Liu
authors.affiliation: a Vaccine R&D Center, National Health Research Institutes, Zhunan Town, Miaoli 350, Taiwan.
authors.forename: Hsin-Wei
authors.initials: HW
authors.lastname: Chen
authors.forename: Pele
authors.initials: P
authors.lastname: Chong
mesh_terms: D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology; D016667:Bacterial Capsules / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D025065:Borrelia burgdorferi / Q000276:immunology; D016360:Clostridioides difficile / Q000276:immunology; D003715:Dengue / Q000517:prevention & control; D053059:Dengue Vaccines / Q000276:immunology; D003716:Dengue Virus / Q000276:immunology; D015195:Drug Design; D006801:Humans; D008074:Lipoproteins / Q000276:immunology*; D009345:Neisseria meningitidis / Q000276:immunology; D014611:Vaccination; D022223:Vaccines, Subunit / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D053059:Dengue Vaccines; D008074:Lipoproteins; C072045:OspA protein; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; C039455:capsular polysaccharide, meningococcal group B
keywords: Braun’s lipoproteins; Clostridium difficile-associated diseases; Toll-like receptor agonist; adjuvant; cervical cancer; dengue virus; lipobox leader sequences; meningococcal group B; subunit vaccine; synthetic adjuvant PAMCSK4